ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development

Stock News

2025/11/13

ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.

"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients," said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. "Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies."

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1190620025"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190620025\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190620025?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190620025","market":"sg","top_or_hot":-1,"title":"ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development","media":"Stock News","content":"<p>ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.</p>\n<p>\"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. \"Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-11-13 10:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.</p>\n<p>\"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. \"Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies.\"</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1190620025","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190620025","pubTimestamp":1763001025,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01672":"歌礼制药-B","01477":"欧康维视生物-B","BK1515":"抗疫概念","BK1191":"制药","BK1574":"生物医药B类股"},"translate_title":"ASC36和ASC35组合进入临床开发，歌礼-B(01672)再次涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1,"01477":1},"content_text":"ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.\n\"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. \"Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}